HC Wainwright Reiterates Buy Rating for Immix Biopharma (NASDAQ:IMMX)

Immix Biopharma (NASDAQ:IMMX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 197.87% from the stock’s previous close.

Immix Biopharma Trading Up 6.8 %

NASDAQ IMMX opened at $2.35 on Monday. Immix Biopharma has a 1-year low of $1.26 and a 1-year high of $6.87. The company has a market capitalization of $64.64 million, a price-to-earnings ratio of -2.76 and a beta of 0.28. The stock’s 50 day moving average is $1.98 and its two-hundred day moving average is $1.94.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). On average, analysts predict that Immix Biopharma will post -0.64 earnings per share for the current year.

Hedge Funds Weigh In On Immix Biopharma

A hedge fund recently raised its stake in Immix Biopharma stock. Geode Capital Management LLC lifted its holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) by 5.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 150,082 shares of the company’s stock after buying an additional 7,954 shares during the quarter. Geode Capital Management LLC owned about 0.55% of Immix Biopharma worth $224,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.